Join collection
Hello, welcome to our official website!
40年见证互联网的探“险”之路——中国互联网保险的诞生与崛起
2019-01-12

40年逐梦前行,40年砥砺奋进,40年硕果累累。改革开放40年,中国实现了从“赶上时代”到“**时代”的伟大跨越,更见证了互联网发展的中国奇迹。

共享单车、移动支付、网购、高铁成为当代中国的“新四大发明”,生活的改变显而易见,时代的变革呼之欲出。互联网保险便是这一时代变革的必然产物,而中国人保作为财险领域的领头企业,亦在互联网的浪潮中不断革新,为用户提供更优质便捷的服务。

互联网保险的萌芽与发展

我国互联网保险始于1997年,中国保险学会和北京维信投资顾问有限公司发起成立第一个面向保险市场和保险公司内部信息化管理需求的中文网站——中国保险信息网。当年该网促成国内第一份网上保单,标志着我国保险业迈入了电子商务的大门。

2000年后,各大保险公司官方网站相继成立,中国人保亦紧跟时代步伐,开始了企业门户的品牌展示及资讯传播。

随着电子商务平台的兴起,互联网市场迎来了新一轮的发展热潮,互联网保险作为一种便捷的投保渠道进入人们视野。中国人保在此阶段开启了电商之路。2012年,腾讯正式开通微信公众平台,随之,“中国人保”官方微信服务号也应运而生,实现了产品与渠道的深度结合。与此同时,在智能手机的全面普及下,用户越来越倾向于使用手机来获取资讯与购买产品,互联网保险顺应用户的行为习惯,逐步由PC端向移动通讯端拓展。为顺应市场及大环境的改变,2014年中国人保重磅推出首款人保“一站式”服务APP,专注于向消费者提供咨询、投保等多项便捷服务,用户足不出户便可轻松享受保险生活。

改革开放40年,中国互联网保险实现跨越式发展,并已建立完善的服务系统。而中国人保自开展电子商务业务以来,陆续开通了全国服务专线、电话销售专线、移动互联平台、“中国人保”微信公众平台等,用户可随时随地享受包括保险知识查询、保险产品购买,以及保险理赔等在内的一站式在线服务;同时中国人保在财险行业内首推直升机救援服务,打造了地空一体的救援通道。

中国人保互联网平台的发展,不仅顺应了改革开放时代发展的潮流,更为用户提供了快捷方便的服务,为人民的生命安全保驾护航。

互联网保险带来生活巨变

创新服务模式 提升用户体验

互联网的发展,创造了****直达消费者的信息通路。在办理保险前,用户可通过网络了解、对比不同的保险产品,极大的减少了信息不对称,让信息更透明。在此基础上,为实现以更**、便捷的服务提升用户体验,中国保险业一直致力于打造并完善线上平台,进行服务模式创新,不断实现服务升级。通过完善的互联网保险平台,用户不仅可以更全面的了解保险产品和投保程序,更可实现网上投保、保险信息咨询、缴费、保单信息查询、理赔等保险全过程。

中国人保一直坚持以用户为中心,以创新服务模式、优化用户体验等形式,强化服务升级。如中国人保APP 专业的“道路救援”服务功能。用户线上一键发起道路救援,即可快速获得救援安排情况等信息反馈,及时跟踪救援队伍的*新进度。而在“拇指理赔”功能中,只要是人保家庭自用车用户,动动手指点击车险理赔,完成“一键报案、三张照片、确认账号”三个简单动作,便可在线自助完成理赔,享受从出险报案到收取赔款的全流程一站式便捷服务。

电子化革新 服务**便捷

互联网保险诞生后,用户在任何地方有保险需求,都可及时在线购买完成投保手续。同时,用户足不出户便可通过互联网保险平台进行电子化支付,一键生成电子保单、电子发票,免去来回奔波之苦。不仅大大简化了中间的繁琐交易环节、节约了用户在各环节的等待时间,同时也有效提升了用户的购买效率。

如中国人保用户在填写购买保险信息后,只需选择电子保单选项,系统将自动生成无纸化电子保单,不仅立刻拥有保险保障,还可在保障期间随时随地上网轻松查阅;办理保险变更、理赔等业务亦无需携带纸质保单,便捷、**之余,也更具环保性。

实现信息共享 构建帮扶平台

如今社会已进入大数据时代,数据渗透到经济社会的各个领域。而保险业作为具有大数据天然属性的产业,加之受大数据、云计算等新兴技术的渗透和影响,正实现行业数据信息的开放共享。得益于此,近年来互联网保险才能够深入扶贫公益事业,让**扶贫从“下乡”走向“在线”。

自创立以来,中国人保就认真履行优秀企业的社会责任,重视对用户、环境、社会的贡献。通过人保官网的“人保扶贫”专区我们可见,中国人保一直响应国家号召、借助互联网平台积极投身慈善事业,开展多项扶贫公益活动。如助力农民脱贫攻坚,通过保险扶贫、特色产业扶贫、公益扶贫等形式,开展定点扶贫;支农惠农强农富农,推动农险升级扩面等。中国人保的助农扶贫公益活动,不仅帮助农民过上更好的生活,更助力构建了产业扶贫和防止返贫机制;而用户买到的农产品也是人保精心挑选的优质好产品,也是企业给予大众的倾情回报与优质回馈之一。

改革开放永无止境,互联网保险平台发展革新永不止步。下一个四十年,中国人保将继续兼顾服务与责任,以更完善强大的互联网平台,为用户提供更优质、更及时、更贴心的服务,为人民的美好生活保驾护航。(转载自北国网


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online